11/18
02:20 pm
eols
Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]
Low
Report
Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]
11/18
11:38 am
eols
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Low
Report
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
11/14
11:31 am
eols
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]
Low
Report
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]
11/9
09:50 am
eols
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]
Low
Report
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]
11/7
08:36 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
11/7
06:17 am
eols
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges [Yahoo! Finance]
High
Report
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges [Yahoo! Finance]
11/6
08:28 pm
eols
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
High
Report
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/6
04:05 pm
eols
Evolus Reports Third Quarter 2024 Results
High
Report
Evolus Reports Third Quarter 2024 Results
11/1
08:15 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
11/1
08:00 am
eols
Evolus to Participate in Stifel 2024 Healthcare Conference
Low
Report
Evolus to Participate in Stifel 2024 Healthcare Conference
10/31
02:07 pm
eols
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation [Yahoo! Finance]
Low
Report
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation [Yahoo! Finance]
10/31
02:02 pm
eols
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
Low
Report
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
10/29
08:00 am
eols
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Medium
Report
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
10/23
08:00 am
eols
Evolus to Report Third Quarter Financial Results on November 6, 2024
Medium
Report
Evolus to Report Third Quarter Financial Results on November 6, 2024
10/11
10:53 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10
12:03 pm
eols
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years [Yahoo! Finance]
Low
Report
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years [Yahoo! Finance]
10/3
08:18 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
9/27
09:00 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/16
09:13 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/13
12:10 pm
eols
Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $16.00 to $20.00. They now have an "overweight" rating on the stock.
Medium
Report
Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $16.00 to $20.00. They now have an "overweight" rating on the stock.
9/13
08:02 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Medium
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
9/9
01:03 pm
eols
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/6
08:00 am
eols
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Medium
Report
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024